Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.58 USD
Change Today +0.01 / 0.64%
Volume 54.1K
AVEO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:22 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

aveo pharmaceuticals inc (AVEO) Snapshot

Open
$1.60
Previous Close
$1.57
Day High
$1.60
Day Low
$1.55
52 Week High
04/22/15 - $2.17
52 Week Low
12/9/14 - $0.61
Market Cap
86.9M
Average Volume 10 Days
1.5M
EPS TTM
$-0.78
Shares Outstanding
55.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AVEO PHARMACEUTICALS INC (AVEO)

aveo pharmaceuticals inc (AVEO) Related Businessweek News

No Related Businessweek News Found

aveo pharmaceuticals inc (AVEO) Details

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Its product candidates under development include Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which has completed Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase I dose escalation study. The company’s development programs also comprise AV-380 Program, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia, which is a multi-factorial syndrome of involuntary weight loss associated with various cancers and diseases outside of cancer. It has strategic partnerships with Ophthotech Corporation; Biodesix, Inc.; St. Vincent’s Hospital Sydney Limited; Biogen Idec Inc.; and Kyowa Hakko Kirin. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

57 Employees
Last Reported Date: 03/6/15
Founded in 2001

aveo pharmaceuticals inc (AVEO) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $504.1K
Executive Officer
Total Annual Compensation: $480.3K
Chief Financial Officer
Total Annual Compensation: $350.9K
Compensation as of Fiscal Year 2014.

aveo pharmaceuticals inc (AVEO) Key Developments

AVEO Oncology Names Keith S. Ehrlich as Chief Financial Officer

AVEO Oncology announced the appointment of Keith S. Ehrlich to the position of chief financial officer. In this role, Mr. Ehrlich will be responsible for the company’s financial and administrative strategy and management, and will serve on the executive leadership team which governs corporate strategy. He will report to Michael Bailey, AVEO’s president and chief executive officer. Mr. Ehrlich has most recently served as Chief Financial Officer of Synta Pharmaceuticals.

AVEO Pharmaceuticals, Inc. expected to report Q1 2015 results on May 6, 2015. This event was calculated by Capital IQ (Created on March 7, 2015).

AVEO Pharmaceuticals, Inc. expected to report Q1 2015 results on May 6, 2015. This event was calculated by Capital IQ (Created on March 7, 2015).

AVEO Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

AVEO Pharmaceuticals, Inc. announced unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported collaboration revenue of $0.115 million against $0.323 million a year ago. Loss from operations was $12.993 million against $16.069 million a year ago. Net loss was $13.894 million or $0.27 per basic and diluted share against $16.725 million or $0.32 per basic and diluted share a year ago. For the year, the company reported collaboration revenue of $18.123 million against $1.293 million a year ago. Loss from operations was $50.449 million against $103.904 million a year ago. Net loss was $52.739 million or $1.01 per basic and diluted share against $107.029 million or $2.10 basic and per diluted share a year ago. The decrease in revenue was primarily due to recognition of an additional $13.7 million of previously deferred revenue as a result of the modification of the company’s arrangement with Biogen Idec. In addition, the company recognized an additional $3.1 million of collaboration revenue in connection with the change in the estimated period of performance associated with the company’s collaboration with Astellas as a result of the termination of the agreement in August 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVEO:US $1.58 USD +0.01

AVEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.91 USD -0.10
Bristol-Myers Squibb Co $64.80 USD -0.23
Exelixis Inc $2.90 USD +0.04
GlaxoSmithKline SAE £11.15 EGP 0.00
Takeda Pharmaceutical Co Ltd ¥6,193 JPY +36.00
View Industry Companies
 

Industry Analysis

AVEO

Industry Average

Valuation AVEO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.6x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVEO PHARMACEUTICALS INC, please visit www.aveopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.